ArticleClinical oral investigations2022
Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.
Article in Clinical oral investigations, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Antibiotic-Loaded Platelet-Rich Fibrin (AL-PRF) as a New Carrier for Antimicrobials: A Systematic Review of In Vitro Studies.International journal of molecular sciences · 2025Pooled it
- Platelet-rich fibrin application after mandibular third molar extraction: an umbrella review.Clinical oral investigations · 2024Pooled it
- Use of Platelet-Rich Fibrin and Platelet-Rich Plasma as Delivery Systems for Natural Compounds: A Systematic Review.Materials (Basel, Switzerland) · 2026Review
- Postoperative healing and recurrence in osteonecrosis of the jaw: influence of risk factors and surgical approach.Clinical oral investigations · 2026Article
- Recent Advances in Regenerative Therapies in Periodontology.Dentistry journal · 2025Review
- Application of Platelet-Rich Fibrin and Concentrated Growth Factors as Carriers for Antifungal Drugs-In Vitro Study.Journal of clinical medicine · 2025Article
- The in vitro antibacterial efficacy of advanced platelet-rich fibrin plus supplemented with metronidazole against Fusobacterium nucleatum.Clinical oral investigations · 2025Article
- Letter to the Editor, "Platelet-Rich Fibrin as a Novel Bio-Carrier for the Transfer of Antibiotics to the Root Canal System".Frontiers in dentistry · 2025Article
- The Role of Autologous Platelet Concentrates as a Local Antibiotic Delivery System: A Systematic Scoping Review.Antibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial effects of clindamycin-loaded platelet-rich fibrin (PRF).Clinical oral investigations · 2024Article
- Using platelet concentrates to treat maxillofacial tissue lesions.Frontiers in bioengineering and biotechnology · 2024Review
- Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization.Frontiers in bioengineering and biotechnology · 2024Review
- Investigation of three common centrifugation protocols for platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam: a prospective trial.Clinical oral investigations · 2023Article
- Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw.International journal of environmental research and public health · 2022Article
- Gradual Drug Release Membranes and Films Used for the Treatment of Periodontal Disease.Membranes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMechanisms of wound healing are often impaired in patients with osteonecrosis of the jaw (ONJ). According to the guidelines for the treatment of this disease, early surgical intervention is indicated. However, surgery often faces complications such as wound healing disorders. The application of platelet-rich fibrin (PRF) after necrosectomy between bone and mucosa may constitute a promising approach to improve surgical results. An aspect that was not investigated until now is that PRF acts as a "bio-carrier" for antibiotics previously applied intravenously. MATERIALS AND
methodsWe investigated the antimicrobial properties of PRF in 24 patients presenting ONJ undergoing systemic antibiosis with ampicillin/sulbactam. We measured the concentration of ampicillin/sulbactam in plasma and PRF and performed agar diffusion tests. Ampicillin/sulbactam was applied intravenously to the patient 10 minutes for blood sampling for PRF. No further incorporation of patients' blood or PRF product with antibiotic drugs was obtained. Four healthy patients served as controls.
resultsOur results revealed that PRF is highly enriched with ampicillin/sulbactam that is released to the environment. The antibiotic concentration in PRF was comparable to the plasma concentration of ampicillin/sulbactam. The inhibition zone (IZ) of PRF was comparable to the standard ampicillin/sulbactam discs used in sensitivity testing.
conclusionsThe results of our study demonstrated that PRF is a reliable bio-carrier for systemic applied antibiotics and exhibits a large antimicrobial effect. CLINICAL RELEVANCE: We describe a clinically useful feature of PRF as a bio-carrier for antibiotics. Especially when applied to poorly perfused tissues and bone such as in ONJ, the local release of antibiotics can reduce wound healing disorders like infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.